Results 141 to 150 of about 23,213 (252)

Management of Non‐Plaque‐Induced Gingival Conditions: A Systematic Review—Part 2: Inflammatory and Immune Conditions; Neoplasms; and Gingival Pigmentation

open access: yesJournal of Clinical Periodontology, EarlyView.
ABSTRACT Aims This systematic review assesses current evidence on the management of non‐plaque (dental biofilm)‐induced gingival diseases and conditions (NPIGDs), including (i) inflammatory and immune conditions, (ii) neoplasms and (iii) gingival pigmentations.
Maria Clotilde Carra   +5 more
wiley   +1 more source

Darier disease—A review highlighting new insights from the Darier Disease International Task Force

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
This review provides a global, clinically focused overview of DD, detailing cutaneous and extracutaneous manifestations, disease classification and severity scoring. It emphasizes early recognition, multidisciplinary management and practical guidance for dermatologists to apply evidence‐based care in diverse skin phototypes. Abstract Darier disease (DD)
Sofia Labbouz   +49 more
wiley   +1 more source

Expert consensus on oral management in autoimmune bullous diseases, erythema multiforme and SJS/TEN

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
This international Delphi study achieved expert consensus on 58 statements guiding the management of oral involvement in autoimmune bullous diseases, erythema multiforme and SJS‐TEN. The recommendations emphasize multidisciplinary care, oral hygiene and tailored topical, systemic and inpatient oral management.
Shalini Nayee   +39 more
wiley   +1 more source

In Vitro Antifungal Activity of Octenidine Against Emerging Dermatophyte Species. [PDF]

open access: yesMycopathologia
Spettel K   +7 more
europepmc   +1 more source

Safety and pharmacokinetics of anumigilimab for hidradenitis suppurativa or palmoplantar pustulosis: A phase 1b study

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Anumigilimab, a novel anti‐G‐CSF receptor antibody, was investigated in a phase 1b trial involving 39 patients with hidradenitis suppurativa or palmoplantar pustulosis. No serious safety concerns related to anumigilimab were noted, and PK and PD were dose dependent.
Johannes S. Kern   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy